Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus bv-77 + bifidobacterium animalis subsp. lactis CP-9
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A probiotic combination consisting of *Lactobacillus rhamnosus* strain bv-77 and *Bifidobacterium animalis* subsp. *lactis* strain CP-9. Developed by Glac Biotech, this live biotherapeutic mixture is primarily investigated for its metabolic effects, particularly in alleviating diet-induced obesity. The mechanism involves the regulation of fat accumulation, lipid metabolism, and the modulation of adipokines such as leptin and adiponectin. The CP-9 strain was originally isolated from human breast milk. The combination is typically administered orally in freeze-dried capsule form and has been evaluated both as a dual-strain mixture and as part of broader multi-strain probiotic formulations for conditions including type 1 diabetes and neonatal jaundice.
- Other names
- Lactobacillus rhamnosus bv-77 + Bifidobacterium animalis subsp. lactis CP-9bv-77 + CP-9
02
Targets
AdipoR (Adiponectin receptor)LEP (Leptin)
Beyond the preview
Go deeper on lactobacillus rhamnosus bv-77 + bifidobacterium animalis subsp. lactis CP-9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus bv-77 + bifidobacterium animalis subsp. lactis CP-9.